Welcome to our dedicated page for RESMED SEC filings (Ticker: RMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on RESMED's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into RESMED's regulatory disclosures and financial reporting.
Filing: Form 4 filed by Brett Sandercock, Chief Financial Officer of ResMed Inc. (RMD), signed 08/04/2025.
On 08/01/2025 Mr. Sandercock reported two non-derivative transactions and one derivative entry. He acquired 2,000 shares of ResMed common stock under a Rule 10b5-1 plan at $101.64 (reported beneficial ownership after this line: 86,283 shares). He disposed of 3,000 shares at $281.90 (reported beneficial ownership after this line: 83,283 shares). Separately, he reported 2,000 option-related derivative securities with an exercise price of $101.64, exercisable from 11/11/2019 and expiring 11/14/2025, leaving 6,000 derivative securities beneficially owned following the report.
Disclosures: The stock transactions were executed under a Rule 10b5-1 plan adopted February 19, 2025. Options vest 1/3 per year.
ResMed Inc. (RMD) Form 4: Global General Counsel & Secretary Michael J. Rider reported a modest open-market sale of company stock.
- Transaction: On 01 Aug 2025 he sold 50 common shares at $281.90 each, generating roughly $14.1k in gross proceeds. The sale was carried out under a pre-arranged Rule 10b5-1 plan adopted 28 Feb 2025.
- Post-sale holdings: Rider now directly owns 8,486 shares; no derivative positions were reported.
The divestiture represents an immaterial decrease in the executive’s stake and an insignificant fraction of ResMed’s total float, suggesting limited market impact. Because the trade was executed under a 10b5-1 plan, timing-related information asymmetry concerns are mitigated. Investors may view the filing as routine but should track subsequent insider activity for trend changes.
ResMed Inc. (RMD) – Form 144 filing: Insider Michael Rider has notified the SEC of his intent to sell up to 50 common shares through Fidelity Brokerage on or about 01 Aug 2025 on the NYSE. The shares carry an estimated market value of $14,095 and originate from restricted-stock vesting on 11 Nov 2021 that was received as compensation.
The filing also discloses earlier open-market sales by Rider in the last three months: 41 shares on 02 Jun 2025 for $9,994.98 and 66 shares on 01 Jul 2025 for $16,961.34. In total, Rider has sold or proposes to sell 157 shares in the period, compared with the company’s 146,627,399 shares outstanding, resulting in a de-minimis ownership impact (<0.001%). No other material terms, lock-ups, or 10b5-1 plan details are provided in the notice.
ResMed Inc. (RMD) – Form 4 insider transaction: Director and Chairman emeritus Peter C. Farrell disclosed the sale of 945 common shares on 07/02/2025 at an average price of $255.49 per share. The trade, executed under a previously adopted Rule 10b5-1 trading plan dated May 28 2024, reduced Farrell’s direct holdings to 68,273 shares. No derivative securities were involved, and no additional transactions were reported.
The disposition represents roughly 1.4% of the insider’s pre-transaction stake and does not change his board status. Because the sale was pre-planned, it typically signals liquidity management rather than an active valuation call.